Skip to main content
Erschienen in: Clinical and Translational Oncology 12/2012

01.12.2012 | Educational Series – Red Series*

Role of gamma-delta T-cells in cancer. Another opening door to immunotherapy

verfasst von: Diego Marquez-Medina, Joel Salla-Fortuny, Antonieta Salud-Salvia

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

The gamma-delta (γδ) T-cells are a subset of T-lymphocytes characterized by the presence of a surface antigen recognition complex type 2. Those γδ T-cells represent 2–5 % of peripheral T-cells only, but they are common in organs and mucosae, acting as a first defense system in the entries to the organism. The γδ T-cells take part on immune response by direct cytolysis, development of memory phenotypes, and modulation of immune cells, and they have been implied in autoimmune disorders, immune deficiencies, infections, and tumor diseases. We reported the role of γδ T-cells in oncology, focusing in their potential applications for cancer treatment. Experimental designs and clinical trials in the treatment of solid malignancies are extensively reviewed.
Literatur
1.
Zurück zum Zitat Acuto O, Hussey RE, Fitzgerald KA, Protentis JP, Meuer SC, Schlossman SF et al (1983) The human T cell receptor: appearance in ontogeny and biochemical relationship of α and β subunits on IL-2 dependent clones and T cell tumors. Cell 34(3):717–726PubMedCrossRef Acuto O, Hussey RE, Fitzgerald KA, Protentis JP, Meuer SC, Schlossman SF et al (1983) The human T cell receptor: appearance in ontogeny and biochemical relationship of α and β subunits on IL-2 dependent clones and T cell tumors. Cell 34(3):717–726PubMedCrossRef
2.
Zurück zum Zitat Chien YH, Iwashima M, Kaplan KB, Elliott JF, Davis MM (1987) A new T-cell receptor gene located within the alpha locus and expressed early in T-cell differentiation. Nature 327(6124):677–682PubMedCrossRef Chien YH, Iwashima M, Kaplan KB, Elliott JF, Davis MM (1987) A new T-cell receptor gene located within the alpha locus and expressed early in T-cell differentiation. Nature 327(6124):677–682PubMedCrossRef
3.
Zurück zum Zitat Hochstenbach F, Brenner MB (1990) Newly identified gamma delta and beta delta T-cell receptors. J Clin Immunol 10(1):1–18PubMedCrossRef Hochstenbach F, Brenner MB (1990) Newly identified gamma delta and beta delta T-cell receptors. J Clin Immunol 10(1):1–18PubMedCrossRef
4.
Zurück zum Zitat Porcelli S, Morita CT, Brenner MB (1992) CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen. Nature 360(6404):593–597PubMedCrossRef Porcelli S, Morita CT, Brenner MB (1992) CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen. Nature 360(6404):593–597PubMedCrossRef
5.
Zurück zum Zitat Hayday AC (2000) [Gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18:975–1026PubMedCrossRef Hayday AC (2000) [Gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18:975–1026PubMedCrossRef
6.
Zurück zum Zitat Itohara S, Nakanishi N, Kanagawa O, Kubo R, Tonegawa S (1989) Monoclonal antibodies specific to native murine T-cell receptor gamma delta: analysis of gamma delta T cells during thymic ontogeny and in peripheral lymphoid organs. Proc Natl Acad Sci USA 86(13):5094–5098PubMedCrossRef Itohara S, Nakanishi N, Kanagawa O, Kubo R, Tonegawa S (1989) Monoclonal antibodies specific to native murine T-cell receptor gamma delta: analysis of gamma delta T cells during thymic ontogeny and in peripheral lymphoid organs. Proc Natl Acad Sci USA 86(13):5094–5098PubMedCrossRef
7.
Zurück zum Zitat Hayday A, Theodoridis E, Ramsburg E, Shires J (2001) Intraepithelial lymphocytes: exploring the Third Way in immunology. Nat Immunol 2(11):997–1003PubMedCrossRef Hayday A, Theodoridis E, Ramsburg E, Shires J (2001) Intraepithelial lymphocytes: exploring the Third Way in immunology. Nat Immunol 2(11):997–1003PubMedCrossRef
8.
Zurück zum Zitat Sanchez-Garcia J, Atkins C, Pasvol G, Wilkinson RJ, Colston MJ (1996) Antigen-driven shedding of l-selectin from human gamma delta T cells. Immunology 89(2):213–219PubMedCrossRef Sanchez-Garcia J, Atkins C, Pasvol G, Wilkinson RJ, Colston MJ (1996) Antigen-driven shedding of l-selectin from human gamma delta T cells. Immunology 89(2):213–219PubMedCrossRef
9.
Zurück zum Zitat Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T et al (2001) MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 15(1):83–93PubMedCrossRef Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T et al (2001) MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 15(1):83–93PubMedCrossRef
10.
Zurück zum Zitat Kong Y, Cao W, Xi X, Ma C, Cui L, He W (2009) The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D. Blood 114(2):310–317PubMedCrossRef Kong Y, Cao W, Xi X, Ma C, Cui L, He W (2009) The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D. Blood 114(2):310–317PubMedCrossRef
11.
Zurück zum Zitat Nedellec S, Sabourin C, Bonneville M, Scotet E (2010) NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals. J Immunol 185(1):55–63PubMedCrossRef Nedellec S, Sabourin C, Bonneville M, Scotet E (2010) NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals. J Immunol 185(1):55–63PubMedCrossRef
12.
Zurück zum Zitat Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, Guiraud M et al (2005) Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22(1):71–80PubMedCrossRef Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, Guiraud M et al (2005) Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22(1):71–80PubMedCrossRef
13.
Zurück zum Zitat Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2):384–392PubMed Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2):384–392PubMed
14.
Zurück zum Zitat Hirsh MI, Hashiguchi N, Chen Y, Yip L, Junger WG (2006) Surface expression of HSP72 by LPS-stimulated neutrophils facilitates gammadeltaT cell-mediated killing. Eur J Immunol 36(3):712–721PubMedCrossRef Hirsh MI, Hashiguchi N, Chen Y, Yip L, Junger WG (2006) Surface expression of HSP72 by LPS-stimulated neutrophils facilitates gammadeltaT cell-mediated killing. Eur J Immunol 36(3):712–721PubMedCrossRef
15.
Zurück zum Zitat Mookerjee-Basu J, Vantourout P, Martinez LO, Perret B, Collet X, Perigaud C et al (2010) F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells. J Immunol 184(12):6920–6928PubMedCrossRef Mookerjee-Basu J, Vantourout P, Martinez LO, Perret B, Collet X, Perigaud C et al (2010) F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells. J Immunol 184(12):6920–6928PubMedCrossRef
16.
Zurück zum Zitat Bonneville M, Fournie JJ (2005) Sensing cell stress and transformation through Vgamma9Vdelta2 T cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect 7(3):503–509PubMedCrossRef Bonneville M, Fournie JJ (2005) Sensing cell stress and transformation through Vgamma9Vdelta2 T cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect 7(3):503–509PubMedCrossRef
17.
Zurück zum Zitat Toutirais O, Cabillic F, Le Friec G, Salot S, Loyer P, Le Gallo M et al (2009) DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells. Eur J Immunol 39(5):1361–1368PubMedCrossRef Toutirais O, Cabillic F, Le Friec G, Salot S, Loyer P, Le Gallo M et al (2009) DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells. Eur J Immunol 39(5):1361–1368PubMedCrossRef
18.
Zurück zum Zitat Ponomarev ED, Dittel BN (2005) Gamma delta T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism. J Immunol 174(8):4678–4687PubMed Ponomarev ED, Dittel BN (2005) Gamma delta T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism. J Immunol 174(8):4678–4687PubMed
19.
Zurück zum Zitat Bonneville M, Scotet E (2006) Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 18(5):539–546PubMedCrossRef Bonneville M, Scotet E (2006) Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 18(5):539–546PubMedCrossRef
20.
Zurück zum Zitat Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, Bernardi G et al (2004) FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood 104(6):1801–1807PubMedCrossRef Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, Bernardi G et al (2004) FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood 104(6):1801–1807PubMedCrossRef
21.
Zurück zum Zitat Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF et al (2008) V gamma 9V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs–rituximab and trastuzumab. Int J Cancer 122(11):2526–2534PubMedCrossRef Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF et al (2008) V gamma 9V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs–rituximab and trastuzumab. Int J Cancer 122(11):2526–2534PubMedCrossRef
22.
Zurück zum Zitat Brandes M, Willimann K, Moser B (2005) Professional antigen-presentation function by human gammadelta T Cells. Science 309(5732):264–268PubMedCrossRef Brandes M, Willimann K, Moser B (2005) Professional antigen-presentation function by human gammadelta T Cells. Science 309(5732):264–268PubMedCrossRef
23.
Zurück zum Zitat Himoudi N, Morgenstern DA et al (2012) Human γδ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol 188(4):1708–1716PubMedCrossRef Himoudi N, Morgenstern DA et al (2012) Human γδ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol 188(4):1708–1716PubMedCrossRef
24.
Zurück zum Zitat Lai X, Shen Y, Zhou D, Sehgal P, Shen L, Simon M et al (2003) Immune biology of macaque lymphocyte populations during mycobacterial infection. Clin Exp Immunol 133(2):182–192PubMedCrossRef Lai X, Shen Y, Zhou D, Sehgal P, Shen L, Simon M et al (2003) Immune biology of macaque lymphocyte populations during mycobacterial infection. Clin Exp Immunol 133(2):182–192PubMedCrossRef
25.
Zurück zum Zitat Kamath AB, Wang L, Das H, Li L, Reinhold VN, Bukowski JF (2003) Antigens in tea-beverage prime human Vgamma 2Vdelta 2 T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses. Proc Natl Acad Sci USA 100(10):6009–6014PubMedCrossRef Kamath AB, Wang L, Das H, Li L, Reinhold VN, Bukowski JF (2003) Antigens in tea-beverage prime human Vgamma 2Vdelta 2 T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses. Proc Natl Acad Sci USA 100(10):6009–6014PubMedCrossRef
26.
Zurück zum Zitat Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C et al (2003) Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 198(3):391–397PubMedCrossRef Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C et al (2003) Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 198(3):391–397PubMedCrossRef
27.
Zurück zum Zitat Caccamo N, Meraviglia S, Ferlazzo V, Angelini D, Borsellino G, Poccia F et al (2005) Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur J Immunol 35(6):1764–1772PubMedCrossRef Caccamo N, Meraviglia S, Ferlazzo V, Angelini D, Borsellino G, Poccia F et al (2005) Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur J Immunol 35(6):1764–1772PubMedCrossRef
28.
Zurück zum Zitat Turner J, Dockrell HM (1996) Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology 87(3):339–342PubMedCrossRef Turner J, Dockrell HM (1996) Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology 87(3):339–342PubMedCrossRef
29.
Zurück zum Zitat Poccia F, Agrati C, Castilletti C, Bordi L, Gioia C, Horejsh D et al (2006) Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells. J Infect Dis 193(9):1244–1249PubMedCrossRef Poccia F, Agrati C, Castilletti C, Bordi L, Gioia C, Horejsh D et al (2006) Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells. J Infect Dis 193(9):1244–1249PubMedCrossRef
30.
Zurück zum Zitat Agrati C, Alonzi T, De Santis R, Castilletti C, Abbate I, Capobianchi MR et al (2006) Activation of Vgamma9Vdelta2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. Int Immunol 18(1):11–18PubMedCrossRef Agrati C, Alonzi T, De Santis R, Castilletti C, Abbate I, Capobianchi MR et al (2006) Activation of Vgamma9Vdelta2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. Int Immunol 18(1):11–18PubMedCrossRef
31.
Zurück zum Zitat Kistowska M, Rossy E, Sansano S, Gober HJ, Landmann R, Mori L et al (2008) Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR gamma delta cells. Eur J Immunol 38(8):2200–2209PubMedCrossRef Kistowska M, Rossy E, Sansano S, Gober HJ, Landmann R, Mori L et al (2008) Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR gamma delta cells. Eur J Immunol 38(8):2200–2209PubMedCrossRef
32.
Zurück zum Zitat Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, Gastman BR et al (2008) Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 14(13):4232–4240PubMedCrossRef Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, Gastman BR et al (2008) Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 14(13):4232–4240PubMedCrossRef
33.
Zurück zum Zitat Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H et al (2007) Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol 66(2–3):320–328PubMedCrossRef Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H et al (2007) Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol 66(2–3):320–328PubMedCrossRef
34.
Zurück zum Zitat Mattarollo SR, Kenna T, Nieda M, Nicol AJ (2007) Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother 56(8):1285–1297PubMedCrossRef Mattarollo SR, Kenna T, Nieda M, Nicol AJ (2007) Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother 56(8):1285–1297PubMedCrossRef
35.
Zurück zum Zitat Burjanadze M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C et al (2007) In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 139(2):206–216PubMedCrossRef Burjanadze M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C et al (2007) In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 139(2):206–216PubMedCrossRef
36.
Zurück zum Zitat Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654–2666PubMedCrossRef Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654–2666PubMedCrossRef
37.
Zurück zum Zitat Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E et al (2005) V gamma 9 V delta 2 T cell response to colon carcinoma cells. J Immunol 175(8):5481–5488PubMed Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E et al (2005) V gamma 9 V delta 2 T cell response to colon carcinoma cells. J Immunol 175(8):5481–5488PubMed
38.
Zurück zum Zitat Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S et al (2005) Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 174(3):1338–1347PubMed Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S et al (2005) Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 174(3):1338–1347PubMed
39.
Zurück zum Zitat Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, Caignard A (2008) Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients. J Immunother 31(3):313–323PubMedCrossRef Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, Caignard A (2008) Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients. J Immunother 31(3):313–323PubMedCrossRef
40.
Zurück zum Zitat Liu Z, Eltoum IE, Guo B, Beck BH, Cloud GA, Lopez RD (2008) Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol 180(9):6044–6053PubMed Liu Z, Eltoum IE, Guo B, Beck BH, Cloud GA, Lopez RD (2008) Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol 180(9):6044–6053PubMed
41.
Zurück zum Zitat Yuasa T, Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N et al (2009) Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 58(4):493–502PubMedCrossRef Yuasa T, Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N et al (2009) Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 58(4):493–502PubMedCrossRef
42.
Zurück zum Zitat Simoni D, Gebbia N, Invidiata FP, Eleopra M, Marchetti P, Rondanin R et al (2008) Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. J Med Chem 51(21):6800–6807PubMedCrossRef Simoni D, Gebbia N, Invidiata FP, Eleopra M, Marchetti P, Rondanin R et al (2008) Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. J Med Chem 51(21):6800–6807PubMedCrossRef
43.
Zurück zum Zitat Boedec A, Sicard H, Dessolin J, Herbette G, Ingoure S, Raymond C et al (2008) Synthesis and biological activity of phosphonate analogs and geometric isomers of the highly potent phosphoantigen (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate. J Med Chem 51(6):1747–1754PubMedCrossRef Boedec A, Sicard H, Dessolin J, Herbette G, Ingoure S, Raymond C et al (2008) Synthesis and biological activity of phosphonate analogs and geometric isomers of the highly potent phosphoantigen (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate. J Med Chem 51(6):1747–1754PubMedCrossRef
44.
Zurück zum Zitat Das H, Wang L, Kamath A, Bukowski JF (2001) Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98(5):1616–1618PubMedCrossRef Das H, Wang L, Kamath A, Bukowski JF (2001) Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98(5):1616–1618PubMedCrossRef
45.
Zurück zum Zitat Monkkonen H, Ottewell PD, Kuokkanen J, Monkkonen J, Auriola S, Holen I (2007) Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci 81(13):1066–1070PubMedCrossRef Monkkonen H, Ottewell PD, Kuokkanen J, Monkkonen J, Auriola S, Holen I (2007) Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci 81(13):1066–1070PubMedCrossRef
46.
Zurück zum Zitat Caccamo N, Meraviglia S, Cicero G, Gulotta G, Moschella F, Cordova A et al (2008) Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer. Curr Med Chem 15(12):1147–1153PubMedCrossRef Caccamo N, Meraviglia S, Cicero G, Gulotta G, Moschella F, Cordova A et al (2008) Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer. Curr Med Chem 15(12):1147–1153PubMedCrossRef
47.
Zurück zum Zitat Sicard H, Ingoure S, Luciani B, Serraz C, Fournie JJ, Bonneville M et al (2005) In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 175(8):5471–5480PubMed Sicard H, Ingoure S, Luciani B, Serraz C, Fournie JJ, Bonneville M et al (2005) In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 175(8):5471–5480PubMed
48.
Zurück zum Zitat Ali Z, Shao L, Halliday L, Reichenberg A, Hintz M, Jomaa H et al (2007) Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vgamma2Vdelta2 T cells in macaques. J Immunol 179(12):8287–8296PubMed Ali Z, Shao L, Halliday L, Reichenberg A, Hintz M, Jomaa H et al (2007) Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vgamma2Vdelta2 T cells in macaques. J Immunol 179(12):8287–8296PubMed
49.
Zurück zum Zitat Vermijlen D, Ellis P, Langford C, Klein A, Engel R, Willimann K et al (2007) Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy. J Immunol 178(7):4304–4314PubMed Vermijlen D, Ellis P, Langford C, Klein A, Engel R, Willimann K et al (2007) Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy. J Immunol 178(7):4304–4314PubMed
50.
Zurück zum Zitat Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C et al (2009) Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res 69(22):8710–8717PubMedCrossRef Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C et al (2009) Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res 69(22):8710–8717PubMedCrossRef
51.
Zurück zum Zitat Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J et al (2005) Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 116(1):94–99PubMedCrossRef Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J et al (2005) Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 116(1):94–99PubMedCrossRef
52.
Zurück zum Zitat Casetti R, Perretta G, Taglioni A, Mattei M, Colizzi V, Dieli F et al (2005) Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2. J Immunol 175(3):1593–1598PubMed Casetti R, Perretta G, Taglioni A, Mattei M, Colizzi V, Dieli F et al (2005) Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2. J Immunol 175(3):1593–1598PubMed
53.
Zurück zum Zitat Gutman D, Epstein-Barash H, Tsuriel M, Golomb G (2012) Alendronate liposomes for antitumor therapy: activation of γδ T cells and inhibition of tumor growth. Adv Exp Med Biol 733:165–179PubMedCrossRef Gutman D, Epstein-Barash H, Tsuriel M, Golomb G (2012) Alendronate liposomes for antitumor therapy: activation of γδ T cells and inhibition of tumor growth. Adv Exp Med Biol 733:165–179PubMedCrossRef
54.
Zurück zum Zitat Zhou J, Kang N, Cui L, Ba D, He W (2012) Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Cell Mol Immunol 9(1):34–44PubMedCrossRef Zhou J, Kang N, Cui L, Ba D, He W (2012) Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Cell Mol Immunol 9(1):34–44PubMedCrossRef
55.
Zurück zum Zitat Dokouhaki P, Han M, Joe B, Li M, Johnston MR, Tsao MS et al (2010) Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: a new approach. Cancer Lett 297(1):126–136PubMedCrossRef Dokouhaki P, Han M, Joe B, Li M, Johnston MR, Tsao MS et al (2010) Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: a new approach. Cancer Lett 297(1):126–136PubMedCrossRef
56.
Zurück zum Zitat Kang N, Zhou J, Zhang T, Wang L, Lu F, Cui Y et al (2009) Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood. Cancer Biol Ther 8(16):1540–1549PubMedCrossRef Kang N, Zhou J, Zhang T, Wang L, Lu F, Cui Y et al (2009) Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood. Cancer Biol Ther 8(16):1540–1549PubMedCrossRef
57.
Zurück zum Zitat Ferrarini M, Heltai S, Pupa SM, Mernard S, Zocchi R (1996) Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors. J Natl Cancer Inst 88(7):436–441PubMedCrossRef Ferrarini M, Heltai S, Pupa SM, Mernard S, Zocchi R (1996) Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors. J Natl Cancer Inst 88(7):436–441PubMedCrossRef
58.
Zurück zum Zitat Kabelitz D, Wesch D, He W (2007) Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67(1):5–8PubMedCrossRef Kabelitz D, Wesch D, He W (2007) Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67(1):5–8PubMedCrossRef
59.
Zurück zum Zitat Kunzmann V, Wilhelm M (2005) Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma 46(5):671–680PubMedCrossRef Kunzmann V, Wilhelm M (2005) Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma 46(5):671–680PubMedCrossRef
60.
Zurück zum Zitat Dieli F, Caccamo N, Meraviglia S (2008) Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more. Curr Opin Investig Drugs 9(10):1089–1094PubMed Dieli F, Caccamo N, Meraviglia S (2008) Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more. Curr Opin Investig Drugs 9(10):1089–1094PubMed
61.
Zurück zum Zitat Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD (2005) Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol 173(5):1552–1556PubMedCrossRef Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD (2005) Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol 173(5):1552–1556PubMedCrossRef
62.
Zurück zum Zitat Saito A, Narita M, Yokoyama A, Watanabe N, Tochiki N, Satoh N et al (2007) Enhancement of anti-tumor cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells. J Clin Exp Hematop 47(2):61–72PubMedCrossRef Saito A, Narita M, Yokoyama A, Watanabe N, Tochiki N, Satoh N et al (2007) Enhancement of anti-tumor cytotoxicity of expanded gammadelta T Cells by stimulation with monocyte-derived dendritic cells. J Clin Exp Hematop 47(2):61–72PubMedCrossRef
63.
Zurück zum Zitat Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T et al (2007) Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56(4):469–476PubMedCrossRef Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T et al (2007) Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56(4):469–476PubMedCrossRef
64.
Zurück zum Zitat Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C et al (2008) Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57(11):1599–1609PubMedCrossRef Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C et al (2008) Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57(11):1599–1609PubMedCrossRef
65.
Zurück zum Zitat Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K (2010) Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res 30(2):575–579PubMed Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K (2010) Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res 30(2):575–579PubMed
66.
Zurück zum Zitat Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F et al (2003) Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102(6):2310–2311PubMedCrossRef Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F et al (2003) Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102(6):2310–2311PubMedCrossRef
67.
Zurück zum Zitat Girlanda S, Fortis C, Belloni D, Ferrero E, Ticozzi P, Sciorati C et al (2005) MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res 65(16):7502–7508PubMedCrossRef Girlanda S, Fortis C, Belloni D, Ferrero E, Ticozzi P, Sciorati C et al (2005) MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res 65(16):7502–7508PubMedCrossRef
68.
Zurück zum Zitat Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S et al (2005) Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19(4):664–670PubMed Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S et al (2005) Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19(4):664–670PubMed
69.
Zurück zum Zitat Marten A, Lilienfeld-Toal M, Buchler MW, Schmidt J (2007) Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J Immunother 30(4):370–377PubMedCrossRef Marten A, Lilienfeld-Toal M, Buchler MW, Schmidt J (2007) Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J Immunother 30(4):370–377PubMedCrossRef
70.
Zurück zum Zitat Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G et al (2007) Targeting human {gamma} delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67(15):7450–7457PubMedCrossRef Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G et al (2007) Targeting human {gamma} delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67(15):7450–7457PubMedCrossRef
71.
Zurück zum Zitat Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G et al (2010) In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 161(2):290–297PubMed Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G et al (2010) In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 161(2):290–297PubMed
72.
Zurück zum Zitat Gomes AQ, Martins DS, Silva-Santos B (2010) Targeting gammadelta T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res 70(24):10024–10027PubMedCrossRef Gomes AQ, Martins DS, Silva-Santos B (2010) Targeting gammadelta T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res 70(24):10024–10027PubMedCrossRef
73.
Zurück zum Zitat Kakimi K, Nakajima J, Wada H (2009) Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer 65(1):1–8PubMedCrossRef Kakimi K, Nakajima J, Wada H (2009) Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer 65(1):1–8PubMedCrossRef
74.
Zurück zum Zitat Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S et al (2007) HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 98(9):1424–1430PubMedCrossRef Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S et al (2007) HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 98(9):1424–1430PubMedCrossRef
75.
Zurück zum Zitat Zocchi MR, Ferrarini M, Rugarli C (1990) Selective lysis of the autologous tumor by delta TCS1+ gamma/delta+ tumor-infiltrating lymphocytes from human lung carcinomas. Eur J Immunol 20(12):2685–2689PubMedCrossRef Zocchi MR, Ferrarini M, Rugarli C (1990) Selective lysis of the autologous tumor by delta TCS1+ gamma/delta+ tumor-infiltrating lymphocytes from human lung carcinomas. Eur J Immunol 20(12):2685–2689PubMedCrossRef
76.
Zurück zum Zitat Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y et al (2010) A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 37(5):1191–1197PubMedCrossRef Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y et al (2010) A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 37(5):1191–1197PubMedCrossRef
77.
Zurück zum Zitat Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T et al (2011) Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study. J Immunother 34(2):202–211PubMedCrossRef Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T et al (2011) Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study. J Immunother 34(2):202–211PubMedCrossRef
78.
Zurück zum Zitat Hannani D, Ma Y, Déchanet-Merville J, Kroemer G, Zitvogel L (2012) Harnessing γδ T cells in anticancer immunotherapy. Trends Immunol 33(5):199–206PubMedCrossRef Hannani D, Ma Y, Déchanet-Merville J, Kroemer G, Zitvogel L (2012) Harnessing γδ T cells in anticancer immunotherapy. Trends Immunol 33(5):199–206PubMedCrossRef
Metadaten
Titel
Role of gamma-delta T-cells in cancer. Another opening door to immunotherapy
verfasst von
Diego Marquez-Medina
Joel Salla-Fortuny
Antonieta Salud-Salvia
Publikationsdatum
01.12.2012
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 12/2012
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0935-7

Weitere Artikel der Ausgabe 12/2012

Clinical and Translational Oncology 12/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.